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Abstract. The deregulation of the epidermal growth factor 
receptor (EGFR) pathway plays a major role in the pathogenesis 
of prostate cancer (PCa). However, therapies targeting EGFR 
have demonstrated limited effectiveness in PCa. A potential 
mechanism to overcome EGFR blockade in cancer cells is 
the autocrine activation of alternative receptors of the human 
EGFR (HER) family through the overexpression of the HER 
receptors and ligands. In the present study, we were interested 
in analyzing if this intrinsic resistance mechanism might 
contribute to the inefficacy of EGFR inhibitors in PCa. To this 
end, we selected two androgen-independent human prostate 
carcinoma cell lines (DU145 and PC3) and established DU145 
erlotinib-resistant cells (DUErR). Cells were treated with three 
EGFR inhibitors (cetuximab, gefinitib and erlotinib) and the 
sensitivity to each treatment was assessed. The gene expression 
of the four EGFR/HER receptors and seven ligands of the HER 
family was analyzed by real-time PCR prior to and after each 
treatment. The receptors expression and activation were further 
characterized by flow cytometry and western blot analysis. 
EGFR inhibition rapidly induced enhanced gene expression 
of the EGF, betacellulin and neuregulin-1 ligands along with 
HER2, HER3 and HER4 receptors in the DU145 cells. In 
contrast, slight changes were observed in the PC3 cells, which 
are defective in the phosphatase and tensin homolog (PTEN) 
tumor suppressor gene. In the erlotinib-resistant DUErR cells, 
the expression of HER2 and HER3 was increased at mRNA and 
protein levels together with neuregulin-1, leading to enhanced 
HER3 phosphorylation and the activation of the downstream 
PI3K/Akt survival pathway. HER3 blockage by a monoclonal 
antibody restored the cytostatic activity of erlotinib in DUErR 
cells. Our results confirm that the overexpression and autocrine 
activation of HER3 play a key role in mediating the resistance to 
EGFR inhibitors in androgen-independent PCa cells.
Introduction
The growth and function of a normal prostate is mainly controlled 
via endocrine and paracrine factors. In this context, androgens 
play a major role by regulating the expression of specific genes 
to maintain the prostate homeostasis (1). When a prostate cancer 
(PCa) develops, the majority of the tumors remain initially 
androgen-dependent and thus, the first-line treatment of PCa is 
based on androgen ablation. However, in many cases the tumor 
cells progress to a hormone refractory state, generating androgen-
independent tumors with increased proliferation and invasion 
capacity. In this situation, the therapeutic options are limited and 
the prognosis is poor (2). The proliferation of the androgen-inde-
pendent PCa cells is mediated principally by autocrine factors, 
such as the epidermal growth factor and their receptors, which 
may interact with the androgen receptor in absence of androgen 
ligand binding, constituting an essential signaling pathway for 
tumor growth, invasion and metastasis (3,4).
The human epidermal growth factor receptor (HER) family 
includes four type 1 transmembrane receptors: EGFR, HER2 
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4). They consist of 
a large extracellular ligand-binding region, a transmembrane 
segment and an intracellular tyrosine kinase domain. Stimulation 
through ligand binding induces the homodimerization or 
heterodimerization of a receptor with another family member 
at the plasma membrane, resulting in the phosphorylation of 
specific tyrosine residues in their cytoplasmic tail that leads to 
the activation of several signaling cascades, predominantly the 
ERK1/2 and the phosphatidylinositol 3-kinase (PI3K)/Akt path-
ways (5). These pathways control multiple biological processes 
like cellular proliferation, differentiation, survival, migration, 
and angiogenesis (6). Of the four receptors, HER2 and HER3 
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are dependent proteins: the HER2 extracellular domain lacks 
ligand-binding capacity, while HER3 has a very weak kinase 
activity (7). However, HER2-HER3 heterodimers are highly 
functional and constitute the most active signaling dimer in this 
family. These receptors are activated by a number of ligands that 
are EGF-related peptide growth factors. They are classified in 
three groups depending on their receptor binding specificity: 
epidermal growth factor (EGF), amphiregulin (AR), epigen, 
and transforming growth factor-α (TGF-α) bind exclusively 
to EGFR; betacellulin (BTC), epiregulin (EPR) and heparin-
binding EGF (HB-EGF) bind to EGFR and HER4; and the 
neuregulin (NRG1-4) family members, NRG1 and NRG2, bind 
to HER3 and HER4, whereas NRG3 and NRG4 bind exclusively 
to HER4 (8). Importantly, HER ligands diversify the pattern of 
receptor activation and can direct different biological responses, 
even when they bind to the same receptor (9). However, the HER 
ligands share a significant degree of functional redundancy, as 
HB-EGF is the only ligand whose absence results in postnatal 
lethality (10).
The HER family, especially EGFR and HER2, are frequently 
deregulated in cancer cells as a result of overexpression, muta-
tions, or increased ligand production (11,12). In general terms, 
their enhanced expression in the tumor correlates with a worse 
clinical outcome (13,14). In the recent years, intense efforts have 
been focused on the development of therapeutic strategies to 
block EGFR and HER2 signaling. Two families of HER-directed 
agents have demonstrated clinical activity and are currently in 
use for the treatment of cancer: monoclonal antibodies (MAbs) 
directed against the extracellular domain of the receptors and 
small molecule tyrosine kinase inhibitors (TKIs) that bind to 
the ATP-binding site of the tyrosine kinase domain of the recep-
tors (15-17). However, the marked differences in the specificity 
and clinical efficiency of the HER inhibitors in different carci-
nomas as well as the development of resistances have limited the 
efficacy of these drugs (18,19). In PCa, EGFR, HER2 and HER3 
expression levels are increased as the disease progresses from 
localized to metastasic and to the androgen-independent state 
and these receptors have long been implicated in the survival of 
androgen-independent prostate cancer cells (20-23). Thus, the 
HER family members have been considered as potential thera-
peutic targets in prostate cancer. However, despite the blockade 
of EGFR or HER2 having demonstrated an ability to inhibit the 
proliferation of human prostate tumor cells (24-26), the clinical 
results have revealed only slight benefit of the HER-targeted 
therapy in patients with androgen-independent PCa both when 
EGFR inhibitors were administered as monotherapy or in asso-
ciation with antiandrogens or chemotherapeutics (27-33). The 
molecular mechanism underlying the low efficiency of EGFR 
inhibitors in human PCa remains to be elucidated.
As tumor cells co-express several HER receptors and 
ligands (34), the blockade of a single HER receptor function 
can be compensated by the cell both increasing the expression 
of alternative HER receptors or upregulating the production of 
HER-ligands, establishing autocrine growth factor loops that 
maintain downstream signaling and cellular proliferation. In a 
previous study, we described the capacity of a subset of breast 
cancer cell lines to compensate for the loss of EGFR receptor 
function after gefitinib treatment by upregulating the expression 
of genes coding for EGF-related ligands, especially EPR, NRG 
and EGF (35). The changes in the expression pattern remarkably 
correlated with the intrinsic degree of sensitivity of the breast 
cancer cells to the antiproliferative effects of gefitinib. Similar 
findings were described for a cetuximab-resistant non-small cell 
lung cancer, which overexpressed HER family ligands, especially 
EGF, AR, HB-EGF and BTC (36), and for human breast cancer 
cells selected for resistance to trastuzumab, which presented 
an amplified ligand-induced activation of HER receptors (37). 
The overexpression of neuregulin has also been involved in the 
resistance of breast cancer cells to EGFR-TKIs (38,39). In addi-
tion, emerging studies are demonstrating that the reactivation 
of HER3 is a prominent mechanism of resistance to the current 
TKIs targeting EGFR and HER2 (40-42).
In this work, we were interested in examining the capacity 
of androgen-independent PCa cells to modulate the expression 
of the HER family members as an intrinsic mechanism of 
resistance to EGFR-targeted therapies. To this end, we have 
analyzed the changes in the expression pattern of different HER 
receptors and ligands in two androgen-independent PCa cell 
lines in response to the treatment with the EGFR-directed anti-
body cetuximab and two EGFR TKIs, gefitinib and erlotinib. 
We have also established an erlonitib-resistant cell line in order 
to further determine the relevance of this molecular mechanism 
in the resistance of prostate cancer cells to EGFR TKIs.
Materials and methods
Reagents. Cetuximab (Erbitux®, Merck-Serono, Darmstadt, 
Germany) and trastuzumab (Herceptin®, Roche, Basel, 
Switzerland) were kindly provided by the pharmacy of the 
Catalan Institute of Oncology (Hospital Dr Josep Trueta, Girona, 
Spain). Erlotinib (Tarceva®) was provided by Roche (London, 
UK) and gefitinib (Iressa®) was obtained from Astrazeneca 
(London, UK). For immunofluorescence assays, the monoclonal 
antibodies against human EGFR, HER2, HER3, and HER4 were 
obtained from Calbiochem (San Diego, CA, USA). The Alexa-
Fluor 488-conjugated goat anti-mouse IgG antibody (Invitrogen, 
Carlsbad, CA, USA) was used as a secondary reagent. The 
rabbit primary antibodies for EGFR, HER2, HER3, HER4, and 
β-actin immunoblotting were from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). The mouse monoclonal antibody 
against phospho HER2 (Tyr1248) was from Thermo Fisher 
(Fremont, CA, USA). The rabbit monoclonal antibodies against 
phospho-AktSer473 and phospho HER3 and the rabbit polyclonal 
antibodies against Akt, ERK1/2, and phospho HER1, as well as 
the mouse monoclonal antibody against Phospho ERK 1/2 were 
all from Cell Signaling Technology (Danvers, MA, USA). The 
mouse monoclonal antibody against NRG-1β was from R&D 
Systems (Minneapolis, MN, USA). The peroxidase-conjugated 
secondary antibodies were from Calbiochem. For neutralizing 
assays, a monoclonal antibody against HER3 (clone H3.105.5) 
was obtained from Calbiochem and the monoclonal antibody 
against NRG-1 (clone C-18) was from R&D Systems.
Cell lines. The PC3 and DU145 cell lines were obtained from the 
American Tissue Culture Collection (Rockville, MD, USA). The 
cells were maintained in Dulbecco's modified Eagle's medium 
supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin (Gibco-BRL, Grand Island, NY, USA) at 37˚C in 
a humidified atmosphere containing 5% CO2. The cells were 
passaged twice a week. The erlotinib DU145-resistant cell line 
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(DUErR) was established by continuously exposing the cells to 
increasing concentrations of erlotinib. Initially the cells were 
treated with their corresponding inhibitory concentration 50 
(IC50) of erlotinib (2.5 µM) for one month. Subsequently, the 
erlotinib concentration in the culture medium was increased 
every month to 5, 10 and 15 µM, and then the cells were 
maintained in continuous culture with the maximum achieved 
dose of erlotinib for three additional months. Control parental 
cells were cultured in parallel and exposed to the phosphate-
buffered saline (PBS) (Gibco-BRL) vehicle.
Growth assays. Exponentially growing cells were seeded at a 
density of 1.5x105 cells per dish in 100-mm diameter dishes. 
The cells were allowed to attach and grow for 72 h in culture 
medium and then gefitinib (15 µM), erlotinib (15 µM), cetux-
imab (500 µg/ml) or a PBS vehicle alone (control cells) were 
added. Just before the treatments and at 24, 48 and 72 h, the cells 
were trypsinized and counted manually in a haemocytometer 
using the trypan blue dye exclusion test. Three independent 
counts were made from each treatment. All experiments were 
conducted in triplicate.
Cell proliferation assays. To assess the cytotoxicity of 
EGFR-inhibitors in DU145, PC3 and DUErR cells, aliquots 
of 4,000 cells were seeded in 96-well plates. Three days 
later, the cells were treated with concentrations ranging 
from 0 to 15 µM of erlotinib, 0 to 15 µM of gefitinib, and 0 to 
500 µg/ml of cetuximab for 72 h. Then, the treatments were 
removed, the cells were washed with PBS and incubated for 
3 h with 100 µl of fresh culture medium together with 10 µl 
of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) (Sigma-Aldrich, St. Louis, MO, USA). The 
medium was discarded and dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) was added to each well to dissolve the purple 
formazan crystals. Plates were agitated at room temperature for 
10 min and the absorbance of each well was determined with 
an absorbance microplate reader (ELx800, BioTek, Winooski, 
VT, USA) at a wavelength of 570 nm. Three replicates were 
used for each experiment. The cell viability was determined 
as a percentage of the untreated control cells, by dividing the 
mean absorbance of each treatment by the mean absorbance of 
the untreated cells. The concentration that reduces cell viability 
by 50% (IC50) was established for gefitinib and erlotinib, while 
the concentration that decreases cell viability by 30% (IC30) 
was determined for cetuximab. Cell proliferation assays were 
also performed in order to evaluate the influence of different 
HER-blocking antibodies on the growth of parental DU145 
cells and DUErR cell, after treating the cells for 72 h with 
either 15 µM of erlotinib, 10 µg/ml of trastuzumab, a human-
ized monoclonal antibody against the extracellular domain of 
HER2, 10 µg/ml of the anti-HER3 blocking antibody H3.105.5, 
10 µg/ml of an anti-neuregulin-1 antibody or by different 
combinations of these compounds.
Quantitative real-time PCR analysis. DU145 and PC3 cells 
were treated for 24 h with a concentration analogous to the IC30 
for cetuximab (350 µg/ml and 500 µg/ml, respectively) or to the 
IC50 for erlotinib and gefitinib (2,5 µM and 15 µM, respectively) 
or with vehicle alone as a control. DUErR cells exposed to either 
erlotinib (15 µM) were also analysed. The cells were washed 
with PBS and immediately trypsinized. The total-RNA from 
each sample was isolated using the RNeasy mini kit (Qiagen, 
Venlo, The Netherlands). The RNA concentration was measured 
using an ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) at 260 nm, and 1 µg of each RNA was 
reverse-transcribed into complementary DNA (cDNA) using the 
High Capacity cDNA Archive Kit (Applied Biosystems, Foster 
City, CA, USA). The expression of the HER family members 
EGFR, HER2, HER3, HER4, EGF, TGF-α, AR, BTC, EPR, 
HB-EGF, and NRG-1 was quantified by real-time PCR using 
a pre-designed, gene-specific TaqMan® probe and primer sets 
(TaqMan® Gene Expression assays, Applied Biosystems). 
Quantitative PCR was performed in a standard 96-well plate 
format using the TaqMan One-Step Universal Master Mix 
(Applied Biosystems) and the 7300 Real-Time PCR system 
(Applied Biosystems). Cycling conditions were 95˚C for 10 min, 
followed by 40 cycles at 95˚C for 15 sec and 60˚C for 1 min. 
All samples were tested in triplicate. The relative quantification 
of the mRNA level (µg/ml) of HER receptors and ligands was 
carried out by preparing a standard curve using known dilutions 
of its corresponding standard RNA. Then, the mRNA level was 
normalized to the mRNA level of the housekeeping gene TATA 
box binding (TBP) protein.
Immunofluorescence analysis. The quantification of HER 
receptor expression on the cell membrane was performed using 
flow cytometry. The cells were analyzed by double immuno-
fluorescence using monoclonal antibodies against human 
EGFR, HER2, HER3 and HER4 (Calbiochem). The cells were 
incubated for 30 min at 4˚C with the primary antibody. After 
washing with PBS, the cells were incubated for 30 min at 4˚C in 
the presence of the Alexa-Fluor 488-conjugated goat anti-mouse 
IgG antibody. Fluorescence was analyzed using a FACSCalibur 
flow cytometer (Becton Dickinson Immunocytometry Systems, 
San Jose, CA, USA) equipped with CellQuest™ software 
(Becton Dickinson). Fluorescence intensity was represented on 
a four orders of magnitude log scale (1-10,000). In each experi-
ment 10,000 cells were analyzed.
Western blot analysis. For western blot analyses, parental 
DU145 cells (exposed to either medium alone or supplemented 
with erlotinib (2.5 µM)) and DUErR cells (continuously exposed 
to erlotinib (15 µM)) were collected and lysed with ice-cold 
lysis buffer containing 1 mM EDTA, 150 mM NaCl, 100 µg/ml 
PMSF, 50 mM Tris-HCl (pH 7.5) and protease and phosphatase 
inhibitor cocktails (Sigma-Aldrich). Protein concentrations 
were determined by Lowry-based Bio-Rad assay (Bio-Rad 
Laboratories, Hercules, CA, USA). Equal amounts of protein 
extracts were electrophoresed on an 8% SDS-PAGE gel, trans-
ferred to nitrocellulose membranes and blocked for 1 h at room 
temperature in a blocking buffer containing 2.5% powdered 
skim milk in PBS-T (10 mM Tris-HCl, pH 8.0, 150 mM NaCl 
and 0.05% Tween-20) to prevent non-specific antibody binding. 
Blots were incubated overnight at 4˚C with the corresponding 
primary antibody diluted in blocking buffer. After washes in 
PBS-T, blots were incubated for 1 h with the corresponding 
secondary antibody, and revealed with a commercial kit (West 
Pico Chemiluminescent Substrate, Pierce Biotechnology, 
Rockford, IL, USA). Blots were reprobed with an antibody for 
β-actin to control the protein loading and transfer.
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Statistical analysis. The statistical analysis was performed 
with the SPSS statistical software for Windows (version 15.0; 
SPSS Inc., Chicago, IL, USA). Quantitative variables were 
expressed as mean and standard error (SE). The normality of 
the data was tested using the Kolmogorov-Smirnov test. The 
differences between data with normal distribution and homoge-
neous variances were analyzed using the parametric Student's 
t-test, otherwise the non-parametric Mann-Whitney U test was 
applied. A value of P<0.05 was considered significant.
Results
Basal expression of HER family receptors and ligands 
in prostate cancer cells. The basal expression of the four 
HER receptors and seven different ligands (EGF, TGF-α, 
AR, BTC, EREG, NRG-1 and HB-EGF) was determined 
according to their mRNA levels in two androgen-independent 
human carcinoma cell lines, DU145 and PC3 cells, which 
are derived from metastases of prostate cancer, to brain 
and bone, respectively. Real-time PCR analyses revealed 
mRNA expression for the four HER receptors in both cell 
lines, although minimal constitutive levels of the HER4 
mRNA were detected (Fig. 1). In the DU145 cells, HER2 
was the receptor with the most prominent mRNA expression, 
followed by EGFR and HER3. EGFR, HER2 and HER3 
showed similar mRNA levels in the PC3 cells. HER2 mRNA 
expression was markedly higher in the DU145 cells than in 
the PC3 cells, while EGFR expression was only moderately 
increased. The receptors expression on the cell surface was 
additionally analyzed by flow cytometry (Fig. 2) confirming 
higher protein levels of both EGFR and HER2 in the DU145 
cells than in the PC3 cells. The membrane expression of 
HER3 was parallel in both cell lines. In accordance with the 
low mRNA levels, a very weak HER4 expression on the cell 
surface was observed in both cell lines. 
Regarding the ligands, a basal gene expression of all 
HER ligands analyzed was detected in both cell lines (Fig. 1). 
Interestingly, each cell line showed a particular expression 
pattern with a primarily expressed HER ligand: EPR was over-
expressed in DU145 cells, while BTC was the principal ligand 
in PC3 cells. This is a typical feature of nearly all the epithelial 
cancer cells, which characteristically deregulate the expres-
sion of one or more members of the HER family (43). Notably, 
neuregulin-1 was the ligand with the lowest mRNA levels in 
both cell lines, particularly in PC3 cells.
Sensitivity of the prostate cancer cells to EGFR inhibitors. The 
sensitivity of the prostate cancer cells to the EGFR inhibitors 
was established according to the concentration of each drug 
required to decrease the cell viability by 50% (IC50) for the 
TKIs erlotinib and gefitinib or by 30% (IC30) in the case of the 
monoclonal antibody cetuximab, as the maximal concentration 
of cetuximab tested (500 µg/ml) did not reduce the cell viability 
by 50% in any cell line. As detailed in Fig. 3A, the IC50 values 
for both TKIs were around 2.5 µM in DU145 cells while values 
were 4 to 5-folds higher in PC3 cells. The IC30 of cetuximab 
was 353 µg/ml in DU145 and higher than 500 µg/ml in the PC3. 
According to these results, the DU145 cells were more sensitive 
to the three anti-EGFR agents than PC3 cells. These observations 
were confirmed in the cell growth assays, where both cell lines 
were treated for up to 72 h with an elevated concentration of each 
compound: 15 µM for erlotinib and gefitinib and 500 µg/ml for 
cetuximab. Analysis of the growth curves (Fig. 3B) showed that 
the proliferation rate of DU145 cells was significantly reduced by 
the three EGFR inhibitors. At 72 h, the cell number was about 
four times lower in the erlotinib- and gefitinib-treated DU145 
cells than in untreated cells, while the cetuximab effect on cell 
growth was more moderated. A more attenuated effect of the 
treatments in the PC3 cells growth was observed.
Effect of the EGFR inhibitors on the expression pattern of 
HER receptors and ligands. The effect of EGFR inhibitors on 
the endogenous expression of HER receptors and ligands was 
determined at the mRNA levels 24 h after treating the cells 
with a concentration analogous to the IC30 for cetuximab, to 
the IC50 for erlotinib and gefitinib, or with vehicle alone as a 
Figure 1. Gene expression pattern of HER family members in DU145 and PC3 cells. The basal mRNA level of each HER receptor (EGFR, HER2, HER3, 
HER4) and ligand (EGF, epidermal growth factor; TGF-α, transforming growth factor-α; AR, amphiregulin; BTC, betacellulin; EPR, epiregulin; NRG-1, neu-
regulin-1; HB-EGF, heparin-binding EGF) was assessed by real-time PCR. Each value was normalized versus the corresponding mRNA level of the TATA 
box binding protein (TBP) constitutive gene. The bars represent the mean value ± SE of three independent quantifications.
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control. Fig. 4 represents the variations in the gene expression 
compared with the corresponding untreated cells. Significant 
changes were observed in the DU145 cells, which overexpressed 
a subset of HER family members, while only minor differences 
were observed in the PC3 cells. The treatment with cetuximab 
and the TKIs caused similar effects on each gene expression 
profile; although in most cases gefitinib induced the most 
marked changes. Remarkably, the inhibition of EGFR in the 
DU145 cell line induced the mRNA overexpression of three 
HER ligands that display different binding affinities: EGF, BTC 
and NRG-1. While EGF exclusively binds EGFR, BTC is a 
potent survival factor that activates both EGFR and HER4 (44) 
and NRG-1 is a HER3 and HER4 ligand that acts as a strong 
mitogenic factor (45). No changes were detected in the mRNA 
levels of epiregulin, which is the most predominantly expressed 
HER ligand in DU145 cells. Along with these changes, the 
Figure 2. Basal protein expression of HER receptors on DU145 and PC3 cells. The expression of HER receptors (EGFR, HER2, HER3 and HER4) on the cell 
surface was determined by flow cytometry after indirect immunofluorescence staining with the corresponding antibodies. Histograms were obtained after 
analyzing 10,000 cells. The fluorescence intensity is shown on a four-decade log scale. Solid lines represent DU145 cells and dashed lines PC3 cells.
Figure 3. Sensitivity of DU145 and PC3 cells to EGFR inhibitors. (A) The concentration of cetuximab (µg/ml) and erlotinib/gefitinib (µM), which inhibit by 
30% (IC30) and 50% (IC50), respectively, the DU145 and PC3 cell viability in 72 h, was determined using the MTT assay. Each value represents the mean ± SE 
of three independent experiments. (B) Cell growth inhibition after exposing DU145 and PC3 cells to cetuximab (500 µg/ml), erlotinib (15 µM) and gefitinib 
(15 µM) or vehicle alone (control). The viable cell number was determined by triplicate 0, 24, 48 and 72 h after each treatment using the trypan blue dye 
exclusion test. The mean value ± SE of three independent experiments are represented in the graphs (*P<0.05 vs. control cells).
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mRNA level of HER2 and HER3 were moderately increased in 
the DU145 cells, while EGFR levels were reduced. Particularly, 
HER4 expression was upregulated four-fold after EGFR 
blockade. HER4 levels were also significantly increased but to a 
lesser extent, after the treatment of the PC3 cells with the TKIs.
Expression of the HER receptors and ligands in erlotinib-
resistant DUErR cells. In order to analyze if the overexpression 
of alternative HER family members might be involved in the 
acquired resistance to EGFR inhibitors in PCa, an erlotinib-
resistant DU145 cell line (DUErR) was established by exposing 
the cells to increasing concentrations (up to 15 µM) of erlotinib 
during three months followed by three additional months of 
cell culture in the maximal concentration of erlotinib. As repre-
sented in Fig. 5, the viability of DUErR cells was not affected by 
increasing concentrations of erlotinib (up to 15 µM) in the cell 
culture (Fig. 5A). DUErR proliferation rate was similar when the 
cells were cultured in the presence of erlotinib (15 µM) or vehicle 
alone (PBS) (Fig. 5B). In contrast, the viability and proliferation 
of the parental DU145 cells was markedly inhibited by erlotinib. 
Notably, the DUErR cell line presented a slower proliferation 
rate compared to the parental DU145 cells (Fig. 5B). DUErR 
cells were also cross-resistant to gefitinib (data not shown).
Next, the mRNA expression profile of HER receptors and 
ligands was determined by real-time PCR in the DUErR cells 
and the differences from the parental control DU145 cells were 
assessed. As shown in Fig. 6, in erlotinib-exposed DUErR 
cells the NRG-1 mRNA expression was significantly amplified 
(more than 2-fold) and TGF-α expression was almost doubled 
compared to parental DU145 control cells. HB-EGF expres-
sion was significantly impaired in these cells. Regarding HER 
receptors, a 2-fold increase in HER2 and HER3 mRNA levels 
was detected in the erlotinib-exposed DUErR cells while slight 
differences in HER4 mRNA levels were observed compared 
with control DU145 cells. Western blot analyses confirmed an 
upregulation of HER2 and HER3 protein expression in erlotinib-
treated DUErR cells and a weak expression of HER4 (Fig. 7A).
HER receptors activation and downstream signaling activity 
in DUErR cells. The activation of EGFR, HER2, and HER3 
receptors and the downstream signaling proteins, Akt and 
ERK1/2, was evaluated in control DU145 cells, erlotinib-
Figure 4. Changes in the gene expression of HER receptors and ligands after EGFR inhibition. (A) DU145 and (B) PC3 cells were treated with either the corre-
sponding IC30 of cetuximab (350 µg/ml and 500 µg/ml, respectively), the corresponding IC50 of erlotinib (2.5 µM and 15 µM, respectively) and gefitinib (2.5 µM and 
15 µM, respectively) or vehicle as a control. After 24 h, the mRNA level of each HER receptor (EGFR, HER2, HER3, HER4) and ligand (EGF, epidermal growth 
factor; TGF-α, transforming growth factor-α; AR, amphiregulin; BTC, betacellulin; EPR, epiregulin; NRG-1, neuregulin-1; HB-EGF, heparin-binding EGF) was 
assessed by real-time PCR in each cell line and values were normalized against the corresponding mRNA expression of the TBP  constitutive gene. Then, the 
change in the expression of each particular gene induced by the treatments was determined by comparing the normalized values in treated cells against the cor-
responding normalized value in the control cells. The bars indicate the mean fold change ± SE of three independent quantifications (*P<0.05 vs. control cells). Bars 
over the dotted line indicate an increase in the gene expression compared to the control cells, while bars under the dotted line represent impaired gene expression 
after the treatment.
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treated DU145 cells and erlotinib-exposed DUErR cells. As 
presented in Fig. 7A, erlotinib treatment completely abolished 
the phosphorylation of EGFR both in DU145 cells and in 
DUErR cells. In DUErR cells, together with the overexpression 
of HER2 and HER3, we detected a marked increased in HER3 
phosphorylation and a more attenuated activation of HER2. 
HER3 overactivation was associated with enhanced levels 
of activated Akt in DUErR cells, while slight effects were 
observed in ERK1/2 phosphorylation (Fig. 7B). In contrast, 
after the acute treatment of DU145 cells for 72 h with erlotinib, 
the phosphorylation of HER3 was not increased compared to 
control cells (Fig. 7A). Thus, the signaling through the HER3/
PI3K/Akt pathway was selectively activated after the prolonged 
exposure of DU145 cells to erlotinib, providing a resistance 
mechanism to the EGFR TKI.
Effect of HER2 and HER3 inhibition on the proliferation of 
parental and erlotinib-resistant DU145 cells. In order to further 
determine the relative contribution of the HER receptors in the 
growth function of parental and erlotinib-resistant DU145 cells, 
both cell lines were exposed to HER2 and HER3 inactivating 
antibodies (trastuzumab and H3.105.5, respectively) at a dose 
of 10 µg/ml for 72 h (46), in presence or absence of erlotinib. 
As shown in Fig. 8A, the proliferation rate of both cell lines 
was unaffected by HER2 inhibition. Trastuzumab also failed 
to decrease the cell proliferation when EGFR signaling was 
inhibited by erlotinib (Fig. 8B). In contrast, the cell growth 
was significantly reduced to half when HER3 was blocked 
both in parental and in erlotinib resistant cell lines (Fig. 8A), 
revealing a key role for HER3 in mediating the proliferation 
of these androgen-independent prostate cells. In addition, the 
combination of erlotinib and the HER3 blocking antibody lead 
to a 25% decrease in the proliferation of parental DU145 cells 
compared with DU145 cells exposed to erlotinib alone. Notably, 
this combination resulted in a 50% reduction in the growth of 
DUErR cells, restoring the cytotoxic activity of erlotinib in these 
cells. These results confirm a key role for HER3 in sustaining the 
proliferation of prostate cells when the signaling through EGFR 
is inhibited. The contribution of neuregulin-1, which is a HER3 
ligand, in activating the cell proliferation was also analyzed 
as our previous results demonstrated that both neuregulin-1 
gene and protein expression was increased after the acute and 
Figure 5. Growth profiles of parental DU145 cells and erlotinib-resistant cells 
(DUErR) exposed to erlotinib. (A) Cells were cultured in medium containing 
increasing concentrations of erlotinib (0, 2.5, 5, 10 and 15 µM) for 72 h and 
the cell viability was determined by MTT assays. (B) DU145 and DUErR 
cells were cultured in medium alone (control) or medium containing 15 µM 
erlotinib (+erlotinib) and the total cell number in each situation was assessed 
by triplicate at different time points (0, 24, 48 and 72 h) using the trypan 
blue dye exclusion test. Each point in the graphs represents the mean ± SE of 
three independent experiments. *P<0.05 vs. control DU145 cells; #P<0.05 vs. 
erlotinib-treated DU145 cells.
Figure 6. Changes in the gene expression of HER receptors and ligands in DUErR cells. The gene expression of each HER receptor (EGFR, HER2, HER3, HER4) 
and ligand (EGF, epidermal growth factor; TGF-α, transforming growth factor-α; AR, amphiregulin; BTC, betacellulin; EPR, epiregulin; NRG, neuregulin; 
HB-EGF, heparin-binding EGF) was determined by real-time PCR in parental DU145 cells (control) and in erlotinib-resistant DUErR cells (cultured in medium 
containing 15 µM erlotinib). Each value was normalized against the corresponding mRNA level of the TBP constitutive gene. Then, the change in the expression of 
each particular gene was assessed in DUErR cells compared to the control cells. The bars represent the mean fold-change ± SE of three independent quantifications 
(*P<0.05 vs. control cells). Bars over the dotted line indicate an increase in the gene expression compared to the control cells, while bars under the line represent 
impaired gene expression after the treatment.
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prolonged exposure of DU145 cells to erlotinib. However, after 
incubating the cells with an antibody against neuregulin-1, we 
observed a very moderate reduction on cell proliferation. These 
results suggest a relative role for neuregulin-1 in promoting the 
cell survival, probably because other ligands, like neuregulin-2, 
may be involved in activating the signaling through HER3 in 
these cells. In addition, a recent work describe that HER3 may 
be activated in a neuregulin-1 independent manner in DU145 
cells (22).
Discussion
EGFR expression is involved in PCa progression and correlates 
with androgen independence and metastasis of prostate cancer 
cells (3,4,47). However, the results of clinical trials involving 
EGFR inhibitors have revealed a reduced efficacy in PCa 
patients (27-29,35). The cooperative nature of the HER family 
might play an important role in the low effectiveness of drugs 
targeting EGFR as the co-expression of different HER members 
in the cancer cell can activate parallel signaling pathways 
to circumvent the inhibition of this specific receptor (6,48). 
Actually, analysis of clinical data has revealed that patients 
overexpressing two or more HER family members develop 
more aggressive malignancies than patients that overexpress a 
single receptor (49-52).
In the present study, we were interested in determining if 
the endogenous expression of alternative HER family members 
might contribute to the inefficacy of EGFR inhibitors in PCa cells. 
To this end, the expression pattern of EGFR, HER2, HER3, and 
HER4 as well as seven ligands of the HER family was assessed 
in the DU145 and PC3 androgen-independent human prostate 
carcinoma cell lines at basal level and after the treatment with the 
EGFR-directed antibody cetuximab and the EGFR TKIs gefi-
tinib and erlotinib. Both cell lines are EGFR-positive, however 
PC3 cells lack the phosphatase and tensin homolog tumor 
(PTEN) gene expression, which is a tumor suppressor protein 
that down-regulates the PI3K/Akt pathway. The loss of PTEN 
results in a continuous signaling though the PI3K/Akt pathway 
independently of the upstream receptor activation (53-55). The 
absence of the PTEN gene is a common feature of PCa, as about 
50% of prostate tumors lack PTEN expression (56). Our results 
showed that the sensitivity to EGFR inhibitors, determined as 
IC50 or IC30 values as well as the inhibition of the cell growth, 
was markedly higher in the PTEN-positive DU145 cells than in 
the PC3 cells. These results are in agreement with a previous 
study, where the sensitivity against erlotinib was strongly 
dependent on PTEN presence in PCa cells (26). In that study, the 
efficacy of erlotinib was inversely related to the EGFR/HER2 
ratio; however, we did not find this association. Our data indicate 
a direct association between EGFR expression levels and the 
effectiveness of the treatments.
Our findings have demonstrated the constitutive co-expres-
sion of different HER receptors and ligands at the mRNA 
level in both PCa cell lines. The expression profile of the HER 
ligands was cell type-specific. Epiregulin was the predominant 
ligand in DU145 cells while betacellulin was the main ligand 
in PC3 cells. Both are EGFR ligands, which is the most largely 
expressed receptor at protein level in both cell lines. Thus, 
Figure 7. HER receptors activation and downstream signaling in control, erlo-
tinib-treated and erlotinib-resistant DU145 cells. (A) Equal amounts of protein 
lysates from parental DU145 cells [exposed to either medium alone (control) 
or supplemented with erlotinib (2.5 µM)] and erlotinib-resistant (DUErR) 
cells [continuously exposed to erlotinib (15 µM)] were immunoblotted with 
anti-EGFR, anti-HER2, anti-HER3, anti-HER4 and anti-neuregulin-1 (NRG1) 
antibodies to determine the protein levels. Receptor activation was analyzed 
by assessing their phosphorylation status using the corresponding phospho-
specific antibody. (B) Total and phosphorylated levels of the ERK1/2 and AKT 
signaling proteins were specifically determined in control DU145 cells and 
erlotinib-exposed DUErR cells. Actin levels were used as loading control.
Figure 8. Effect of EGFR, HER2 and HER3 inhibition on the proliferation 
of parental and erlotinib-resistant DU145 cells. DU145 and DUErR cells 
were exposed for 72 h to antibodies directed at either HER2 (trastuzumab), 
HER3 (anti-HER3) or neuregulin (anti-NRG1) alone (A) or combined with 
erlotinib (15 µM) (B) and the relative cell proliferation versus untreated 
(control) DU145 cells was assessed. Each column in the graph represents 
the mean ± SE of three independent experiments. *P<0.05 vs. DU145 control 
cells; **P<0.05 vs. DUErR control cells; #P<0.05 vs. erlotinib-treated DU145 
cells; ##P<0.05 vs. erlotinib-treated DUErR cells.
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tumor cell proliferation could be sustained autonomously by 
the autocrine production of growth factors. In fact, both cell 
lines were able to proliferate independently of the exogenous 
supply of growth factors in the cell culture (data not shown). 
Highly increased expression of epiregulin and amphiregulin, 
together with TGF-α and HB-EGF, has been previously 
described in androgen-independent prostate cancer compared 
to normal prostate epithelial cells or androgen-sensitive cancer 
cells (57,58). Epiregulin and amphiregulin expression also 
increased after androgen deprivation in an androgen-sensitive 
prostate cancer xenograft, indicating that these growth factors 
might contribute to the tumor progression to an androgen-
independent stage (59). In addition, the expression of epiregulin 
in breast cancer cells together with further three genes was 
identified as a key determinant for pulmonary metastasis (60). 
Epiregulin and amphiregulin gene expression has also been 
associated with the development of liver metastasis in colorectal 
cancer patients (61). Our group and others have recently reported 
that an elevated gene expression of epiregulin and amphiregulin 
in cancer cells might be a predictive marker of the therapeutic 
response to cetuximab (62,63). In keeping with this observation, 
the epiregulin-overexpressing DU145 cells were markedly more 
sensitive to cetuximab than the PC3 cell line.
In response to inhibition of EGFR signaling by cetuximab, 
gefitinib and erlotinib treatments, the gene expression of EGF, 
betacellulin and neuregulin ligands along with the HER2, 
HER3 and HER4 receptors was significantly increased in the 
DU145 cells. Interestingly, the alternative binding affinities of 
these ligands might activate all possible HER heterodimers to 
compensate the loss of EGFR function and preserve the EGFR 
downstream cell signaling. In contrast, slight differences in the 
mRNA levels of HER family members were observed in the PC3 
cell line, which only upregulated HER4 expression, indicating 
that the autocrine growth factor loops are attenuated when the 
signaling activity through the EGFR pathways is constitutively 
activated independently of ligand binding. While the upregu-
lation of HER2 and HER3 was moderate in DU145 cells, the 
mRNA levels of HER4 were increased by four times after EGFR 
inhibition. A few studies have analyzed the role of HER4 receptor 
in PCa, and the conclusions are controversial. Some investigators 
have correlated the expression of HER4 with enhanced prostate 
cell proliferation and migratory capacity (64,65), but others 
have reported that HER4 has a tumor-suppressive effect (66,67). 
HER4 activity has also been related to acquired resistance to 
anti-EGFR therapies, as the signaling through the PI3K/Akt 
survival pathway can be alternatively activated by HER4 (39). 
Although we have observed a marked increase in HER4 mRNA 
levels shortly after EGFR inhibition, the low protein expression 
of HER4 in DU145 cells suggest a reduced contribution of this 
receptor to overcome EGFR blockade.
There is growing evidence that tumor cells might circum-
vent the effects of EGFR inhibitors through the promotion 
of HER3/HER2 heterodimerization and the activation of the 
PI3K/Akt pathway (38,45,61,68-70). Our results confirm the 
relevance of HER3 in mediating resistance to EGFR TKIs 
in androgen-independent prostate cancer cells. The erlotinib- 
resistant (DUErR) cells, as well as the parental DU145 cells, 
showed a strong dependence on HER3 for proliferation, as 
HER3 neutralization lead to a significant reduction in the 
growth of both cell lines. The prolonged exposure of DU145 
cells to erlotinib induced a reprogramming of HER family 
members expression and HER2 and HER3 levels were 
significantly upregulated, along with neuregulin-1, which is 
a HER3 natural ligand, and TGF-α, which exclusively binds 
EGFR. Ligand-activated HER3 might be then transactivated 
by heterodimerization with HER2, or even with relatively low 
levels of active EGFR, leading to an enhanced activity through 
the PI3K/Akt survival pathway and, thus providing a plausible 
escape mechanism to the EGFR blockade. Importantly, HER3 
inhibition rendered the DUErR cells sensitive to erlotinib, indi-
cating a key role for this receptor in driving the resistance to 
EGFR-targeted therapies in PCa cells.
HER ligands have also been considered as targets for cancer 
therapy, as the loss of HER receptors function can be balanced 
by the endogenous expression of their cognate ligands by cancer 
cells. However the redundancy of ligands for each receptor 
may limit the effectiveness of this strategy, leading to a general 
consensus that inhibiting the receptor function is more effective 
than inhibiting multiple ligands. Our results are in keeping with 
this hypothesis, as the proliferation of the cells was prominently 
reduced after blocking the HER3 receptor, while targeting a 
particular ligand, neuregulin-1, revealed a minor effectiveness 
in reducing the cell growth.
In conclusion, our results show the ability of the androgen-
independent PCa cells to rapidly modulate the expression of 
HER receptors and ligands to sustain the cell proliferation 
after EGFR blockage and a central role for HER3 in mediating 
resistance to EGFR inhibition. This molecular mechanism 
might be especially relevant in the physiological conditions, 
as the proliferation of malignant prostate cells is markedly 
dependent on the autocrine release of growth factors as well 
as the expression of their corresponding receptors in the 
tumor microenvironment. Therefore, the clinical efficacy of 
the current therapeutic approaches targeting EGFR in prostate 
cancer might be improved by the dual inhibition of EGFR and 
HER3 receptors.
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